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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
nature publishing group
Hemolysis and AKI  
in cardiac surgery
Hemolysis, due to mismatched blood 
transfusion, used to be one of the classic 
causes of acute renal failure. However, 
the improvement in cross-matching 
not only eliminated this cause but 
also seemed to throw into question 
whether free hemoglobin is indeed 
a renal toxin. Vermeulen Windsant 
et al. studied 35 patients undergoing 
on-pump repair of aortic aneurysms, 
19 of whom experienced acute kidney 
injury (AKI). Plasma free hemoglobin 
increased during surgery. Remarkably, 
the tubule injury marker N-acetyl-β-
d-glucosaminidase also increased in 
excretion in all patients, regardless of 
the presence of AKI. There was a good 
correlation between the levels of plasma 
free hemoglobin and the urine biomar-
ker, which, in turn, was associated with 
the postoperative increase in serum cre-
atinine. These studies resurrect attention 
to the role of free hemoglobin in renal 
injury. New studies have suggested that 
free hemoglobin might participate in 
scavenging nitric oxide and, hence, pro-
mote renal ischemia and hypo perfusion. 
See page 913.
Metformin 
ameliorates 
aminoglycoside 
nephrotoxicity
Because metformin has been shown to 
reduce apoptosis, Morales et al. tested 
its effect on gentamicin nephrotoxicity. 
Metformin blocked the development of 
gentamicin-induced acute renal failure in 
rats. To examine the potential mechanism 
of protection, the authors conducted an 
extensive study of mitochondrial func-
tion and found that gentamicin depleted 
respiratory components, causing an 
increase in reactive oxygen species gen-
eration. Metformin also ameliorated the 
increased release of cytochrome c from 
kidney mitochondria. While the mecha-
nism of this effect remains obscure, the 
effect was sufficiently significant to make 
follow-up of these studies necessary. 
See page 861.
Iron-based 
phosphate binder
Hyperphosphatemia is a major risk factor 
for vascular calcification, now thought to 
be the major cause of mortality and mor-
bidity in end-stage kidney disease. Hyper-
phosphatemia is associated with rapid 
progression of chronic kidney disease. 
Hence, control of the serum phosphate 
during renal failure is a major challenge 
in our field. However, this control has 
been problematic. As they report in this 
issue, Block et al. treated 44 hemodialy-
sis patients to test the safety and efficacy 
of a novel iron-based phosphate binder, 
SBR759. Using a dose escalation regimen, 
they found that serum phosphate declined 
across all dose ranges. The KDOQI target 
was reached at the end of the first week 
of treatment in all patients. The drug was 
well tolerated within a reasonable dos-
age range, and there were no changes in 
standard iron indices. These studies are 
promising and warrant a more compre-
hensive trial.  See page 897.
